A vaccine that uses cancer cells against themselves significantly slows the progress of a deadly form of blood cancer, a researcher said at the annual meeting of the American Society of Clinical Oncology (ASCO).
In patients with follicular non-Hodgkin's lymphoma, the vaccine -- dubbed BiovaxID -- nearly doubled the time before the disease recurred, compared with a control drug, according to Dr. Stephen Schuster of the University of Pennsylvania School of Medicine in Philadelphia. Link
No comments:
Post a Comment